Flavoxate Hydrochloride

CHEMBL1200875 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
427.9 g/mol
LogP
Phase
4

This hydrochloride salt form of flavoxate is used to relieve discomfort associated with urinary tract conditions, including frequent urination and bladder spasms. It relaxes bladder smooth muscle through multiple mechanisms to reduce urinary symptoms.

分子量

427.9000 g/mol

TPSA

55.80 Ų

治疗领域

作用机制

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl

InChI

InChI=1S/C24H25NO4.ClH/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25;/h2,4-5,8-12H,3,6-7,13-16H2,1H3;1H

Molecular Formula

C24H26ClNO4

HBD / HBA

1 / 5

可旋转键数

6

重原子数

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This hydrochloride salt form of flavoxate is used to relieve discomfort associated with urinary tract conditions, including frequent urination and bladder spasms. It relaxes bladder smooth muscle through multiple mechanisms to reduce urinary symptoms.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Flavoxate Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200875. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441345. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.